Oryzon Genomics S.A. (BME:ORY)
Spain · Delayed Price · Currency is EUR 2.940
+0.022 (0.75%)
Aug 7, 2026, 12:56 PM CET
Oryzon Genomics Revenue
In the year 2025, Oryzon Genomics had annual revenue of $13.70M USD with 73.83% growth.
Revenue
$13.70M
Revenue Growth
+73.83%
P/S Ratio
15.52
Revenue / Employee
$297.76K
Employees
46
Market Cap
239.17M EUR
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 13.70M | 5.82M | 73.83% |
| Dec 31, 2024 | 7.88M | -7.98M | -50.31% |
| Dec 31, 2023 | 15.86M | -1.26M | -7.34% |
| Dec 31, 2022 | 17.11M | 4.85M | 39.56% |
| Dec 31, 2021 | 12.26M | 545.27K | 4.65% |
| Dec 31, 2020 | 11.72M | 146.99K | 1.27% |
| Dec 31, 2019 | 11.57M | 3.36M | 40.98% |
| Dec 31, 2018 | 8.21M | 2.52M | 44.42% |
| Dec 31, 2017 | 5.68M | 14.63K | 0.26% |
| Dec 31, 2016 | 5.67M | 1.02M | 21.97% |
| Dec 31, 2015 | 4.65M | -15.21M | -76.60% |
| Dec 31, 2014 | 19.86M | 15.61M | 367.13% |
| Dec 31, 2013 | 4.25M | -2.47M | -36.78% |
| Dec 31, 2012 | 6.72M | -1.01M | -13.07% |
| Dec 31, 2011 | 7.73M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Grifols | 7.42B |
| Almirall | 1.16B |
| Laboratorios Farmaceuticos Rovi | 773.05M |
| Faes Farma | 711.06M |
| Laboratorio Reig Jofre | 337.73M |
| Clínica Baviera | 320.15M |
| Prim, S.A. | 251.89M |
| Atrys Health | 144.31M |
Oryzon Genomics News
- 10 days ago - Oryzon Q2 Net Loss Narrows; Vafidemstat Advances Towards Phase III Trial In BPD Aggression - Nasdaq
- 10 days ago - Oryzon Genomics Earnings release: Q2 2026 - Filings
- 4 weeks ago - Oryzon Genomics Secures U.S. Patent For Vafidemstat In Borderline Personality Disorder - Nasdaq
- 2 months ago - Oryzon Genomics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 3 months ago - ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31st, 2026 - GlobeNewsWire
- 3 months ago - Oryzon Genomics Earnings release: Q1 2026 - Filings
- 3 months ago - ORYZON to Present Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia at EHA 2026 - GlobeNewsWire
- 5 months ago - Oryzon Genomics announces patent grant decision in Mexico - TheFly